nature reviews | nephrology volume 6 | FeBruarY 2010 | 61 editorial S everal recent publications have used the terms 'aldosterone escape' and 'aldosterone break through' interchangeably. this tendency obscures the pathophysiology of these different processes, both of which have very important clinical implications. administration of large doses of aldosterone typically causes an initial decrease in urinary sodium ex cretion, which leads to renal sodium retention. However, urinary sodium excretion subsequently increases to balance sodium intake before detectable edema devel ops. this phenomenon, termed 'aldos terone escape' , is the reason why edema formation is not a charac teristic of primary hyperaldosteronism. the process of aldo sterone escape invokes several mechanisms. in addi tion to increasing renal perfusion pressure, the resultant volume expansion decreases proximal sodium reabsorp tion and increases sodium delivery to the distal nephron sites of mineralo corticoid action. this increased delivery of sodium overrides the enhanced aldosterone sodium reabsorption at the site of mineralocorticoid action. moreover, volume expansion, secondary to the action of aldo sterone, increases levels of plasma natriuretic hormone and therefore its inhibitory effect on sodium reabsorption in the collecting duct. together, these events contribute to normal aldosterone escape and the prevention of edema.
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in edematous disorders including cardiac failure and cirrhosis, however, normal aldosterone escape is impaired. underfilling of the arterial circulation in cardiac failure secondary to decreased cardiac output or primary systemic arterial vasodilation in cirrhosis activates the neurohumoral axis, stimulating the reninangiotensin-aldosterone system (raas) and the sym pathetic nervous system. in this setting, the decrease in renal perfusion pressure, the decline in glome rular filtration rate, and the increase in proximal tubule re absorption diminish the distal delivery of sodium to the sites of aldosterone and natriuretic hormone action in the collecting ducts. these processes lead to impaired aldosterone escape and blunt the actions of natriuretic hormone, resulting in edema formation (schrier, r. w. the aldosterone breakthrough phenomenon describes a totally different process from aldosterone escape. recognition of the circulating and intrarenal role of the raas in various disease states, including hypertension and the edematous disorders, led to the development of angiotensin converting enzyme (aCe) inhibitors that decrease levels of circulating angiotensin ii and aldo sterone. the angiotensin receptor blockers (arBs) were subsequently developed, which inhibit the action of type 1 angiotensin ii receptors with a resultant decrease in aldosterone level. aCe inhibitors and arBs are now widely used with beneficial effects, particularly in patients with hypertension and cardiac failure. However, since angiotensin ii inhibits renin release, a large increase in plasma renin activity occurs with the admini stration of either aCe inhibitors or arBs. moreover, after several weeks of aCe inhibition or arB therapy, plasma aldo sterone returns to pretreatment levels in up to 30-40% of patients. this phenomenon has been termed aldo sterone breakthrough (Bomback, a. & Klemmer, P. Nat. Clin. Pract. Nephrol. 3, 486-492; 2007) . reports that those patients who demonstrate aldosterone breakthrough have a worse clinical prognosis than those who do not demonstrate aldosterone breakthrough also exist. this deleterious effect could be due to the nongenomic effects of aldosterone, which are known to cause inflamma tion, fibrosis and oxidant injury. whether addition of a mineralocorticoid antagonist to the treatment regimen would ameliorate the proposed negative clinical conse quences of aldosterone breakthrough in these patients is not known.
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of note, direct renin inhibition, for instance with aliskiren, does not increase plasma renin activity, and therefore may not be associated with aldosterone break through. Direct renin inhibitors affect the enzymatic action of renin, but not its production or interaction with the renin receptor. the effect of renin on the renin recep tor has been proposed to be profibrotic (nguyen, G. et al. J. Clin. Invest. 109, 1417 -1427 2002) . of further interest, vitamin D has been shown to bind to the promoter region of the renin gene and downregulate renal messenger rna expression of renin (Doorenbos, C. r. C. et al. Nat. Rev. Nephrol. 5, 691-700; 2009) . therefore, direct renin inhibitors, vitamin D or a combination of the two could theoretically exert a renal and/or cardiovascular protec tive effect in patients receiving aCe inhibitor or arB treatment who demonstrate aldosterone breakthrough. doi:10.1038/nrneph.2009.228 
